• Wellth

  Participated · Series C · Aug 2025

  Wellth combines daily motivation, behavioral economics, and financial incentives to drive measurable behavior change for patients, encouraging actions like medication taking, blood pressure and glucose checks, and preventive visits. Its app delivers social‑media–like daily engagement designed to reach historically hard‑to‑reach Medicare Advantage, Medicaid, and D‑SNP populations. To date members have completed over 50 million daily check‑ins, achieving an average 90% care‑plan adherence, a 51% reduction in inpatient admissions, and a 16% improvement in medication adherence (PDC); the platform has helped partners attain 4+ Star ratings on Medicare Part C and D measures and reduce avoidable costs. Wellth will use new funding to broaden access across high‑need populations, accelerate product innovation and partner growth, and introduce generative AI capabilities to personalize motivation and care journeys. The company emphasizes a decade plus of behavioral data and outcomes as the basis for scaling its Daily Care Motivation approach. Wellth is based in Los Angeles and has been operating for 11 years. Wellth is a digital health company that applies behavioral economics and machine learning to drive daily health behaviors via a mobile app. Users perform simple daily tasks—such as snapping photos of medications or glucose readings—to form habits and increase adherence. The platform reports 91% daily member engagement and outcomes including a 42% average reduction in inpatient utilization, a 29% reduction in ED utilization, and a 16% improvement in medication adherence. Wellth's customers include health plans and provider organizations, and clients have measured cost savings and improved Medicare Advantage Star ratings. Founded in 2014 and headquartered in Los Angeles, the company has achieved impressive annual growth. The new capital will be used to further invest in the behavioral science engine behind the app and to expand the team to support a growing member base. Wellth provides a platform that uses behavioral economics, financial incentives and nudges to improve patient treatment adherence. Members submit scheduled virtual check-ins—typically daily—such as photos of medication or readings from glucometers and blood pressure cuffs. Check-ins are processed immediately by Wellth’s AI technology for verification, and insights can be relayed directly to care teams. Members keep an endowed daily amount and “cash out” at milestone intervals, creating instant gratification and reinforcing healthy habits. Led by CEO and co-founder Matthew Loper, the company plans to use new capital to expand its platform to new use cases. Wellth is based in New York City and recently raised a new funding round to support growth. Wellth is a Brooklyn-based behavioral economics startup that works with insurers and risk-bearing providers to motivate patient behavior change and treatment adherence. Its core product is a mobile patient experience that delivers daily contextual and personalized nudges and quick 'check-ins' for daily medications, using financial incentives and behavioral economics strategies. The company focuses on costly chronic diseases where poor adherence drives preventable hospitalizations and readmissions, including Type 2 Diabetes, Congestive Heart Failure, Cardiovascular Disease, COPD, Asthma and Behavioral Health. Wellth is led by CEO and co-founder Matt Loper. The company recently raised $5.1M in a Series A round to continue expanding its team and platform. It aims to help payers and providers better understand and improve patient behaviors to reduce costs associated with chronic disease management. Wellth is a digital health startup whose app tracks medication adherence, records weight, and uses incentives to motivate healthier lifestyle changes. CEO and co-founder Matt Loper said the company will use new funding to enable full-scale commercial implementations. Wellth has planned launches over the next six months and intends to generate data on interventions in type 2 diabetes, congestive heart failure, and post–heart attack discharge. The company’s near-term goal is to execute those implementations and publish data on impacts to adherence, health outcomes, and healthcare costs. Customers are insurers and risk-bearing providers, particularly in commercial and managed Medicaid markets, and Wellth typically charges on a per-user basis. The company says its actuarial model projects 4x+ returns after accounting for incentive payouts and Wellth fees.

• Wirelane

  Led · Series B · Aug 2023

  Wirelane designs, installs, operates and markets public and private EV charging infrastructure and offers advanced charging hardware, a digital management platform, billing services, and end-to-end installation and operation support. The company serves hotels, real-estate customers and municipalities and is positioned as a preferred partner for public charging projects. Wirelane plans to rapidly expand its network, targeting around 3,000 charging points in over 450 municipalities by the end of 2023, with a focus on urban residential areas. In August it acquired Köln-based On Charge (now trading as Wirelane Public Charging Germany GmbH) to broaden its public charging footprint where people live. Financially, Wirelane completed an €11M Series B expansion to continue its growth trajectory. Founded in 2016 and based in Munich, the company aims to become one of the leading charging infrastructure providers in Germany. Wirelane offers end-to-end charging infrastructure solutions, including installation, operation and marketing, delivered via its cloud-based WirelaneOS. The platform currently manages over 13,000 charging stations and, as an Electric Mobility Provider, offers access to more than 95,000 public charging points across Europe. Wirelane processes over 60,000 charging transactions per month and serves clients across hospitality, property, large corporations and public-sector customers. Since its founding in 2016 the company has operated from offices in Munich and Berlin and works with customers including BMW and Vattenfall. With fresh growth capital, Wirelane plans to expand product development, sales and operations and to scale installation activity significantly over the coming years. Management has said the company aims to build a five-figure number of charging stations in the next three years and to onboard hundreds of new B2B customers in the near term.

• Exosome Diagnostics

  Participated · Series C · Jul 2017

  Exosome Diagnostics develops and commercializes exosome‑based, biofluid diagnostics using its ExoLution™ platform and point‑of‑care instrumentation ShahkyTM. Its flagship offering is the ExoDx® Prostate (IntelliScore) test, and the company is commercializing additional oncology diagnostic tests. Management plans to expand into other areas including neurodegenerative diseases, transplant rejection monitoring, and cardiology. Exosome Diagnostics is building out a companion diagnostics (CDx) business and expanding placement of exosomal instrumentation while advancing point‑of‑care clinical development. Technology differentiators cited include one‑reaction RNA and cell‑free DNA interrogation for signal enhancement and the ability to isolate disease‑specific exosomes by tissue type. The company completed a $30 million Series C financing to support rapid commercial expansion and further commercialization of its technologies. Exosome Diagnostics develops an exosome-based liquid biopsy platform that isolates and analyzes exosomal RNA, DNA and proteins from biofluids to enable non-invasive molecular diagnostics. The company’s tests analyze exoRNA for cancer biomarkers and its platform can simultaneously interrogate exoRNA and cell-free DNA to enhance detection of rare mutations. Exosome Diagnostics also highlights protein biomarker interrogation capabilities to broaden its diagnostic scope. The company plans to launch combined RNA-plus-DNA commercial liquid biopsy tests and pursue potential companion-diagnostic programs with pharma. It intends to expand development beyond oncology into areas such as neurodegenerative, inflammatory, metabolic, and cardiovascular diseases. Financially, Exosome Diagnostics completed a $60 million Series B financing to support growth of its commercial diagnostics, regulatory, and companion-diagnostics divisions and to advance new test and biomarker development. Exosome Diagnostics develops exosome-based molecular diagnostics that isolate and analyze exosomal RNA (exoRNA) and can also analyze cell-free DNA (cfDNA) from biofluids such as plasma, urine and saliva. Its liquid biopsy tests analyze exoRNA for cancer biomarkers and the platform is positioned to be applied to non-oncology indications as well. The company announced a $17.6M extension of its Series B, bringing the total Series B financing to $44.7M, and said the funds will support commercial and development efforts. Planned near-term commercial launches in 2015 include two blood-based lung cancer liquid biopsies (detecting ALK and T790M mutations), a urine-based prostate cancer liquid biopsy, and a 26-gene solid tumor panel offered initially as an LDT. It is developing a next-generation solid tumor panel planned for 2016 to detect 88 genes and thousands of mutations, and is beginning early development of diagnostics for neurodegenerative diseases. Management says the financing positions the company to transition to a commercial-stage company and expand its exosome-based tests across additional disease areas. Exosome Diagnostics develops fluid-based molecular diagnostic tests that analyze exosomes and other microvesicles in biofluids (blood, urine, cerebrospinal fluid) to detect disease-specific genetic material. Led by CEO James McCullough, the company positions its platform for personalized medicine and oncology applications. Planned near-term product launches include EXO106 (a prostate-cancer diagnostic to reduce unnecessary biopsies) and exoRNeasy research kits for RNA extraction targeted for Q2 2014. Under an expanded collaboration with QIAGEN the company is developing EXO501, a blood-based test to measure an actionable mutation in non-small cell lung cancer for non-invasive, repeated tumor mutation assessment. It is also developing EXO1000, a blood-based multi-gene clinically actionable biomarker panel for oncology. The company will use the new funding to support these product launches and continued R&D of its proprietary technology platform. Exosome Diagnostics develops exosome-based molecular diagnostics that detect cancer-specific genes from standard blood and urine samples. Its proprietary exosome technology enables minimally invasive testing for disease stratification and monitoring patient response to treatment. The company aims to further develop and commercialize a series of body-fluid-based oncology diagnostics using the new capital. Exosome Diagnostics is establishing R&D and service operations in New York and Munich to support development and commercialization. In conjunction with the financing it incorporated Exosome Diagnostics GmbH as a wholly owned subsidiary to serve as the European center for development and services. The company raised $20M in equity funding to advance these efforts.

• leon nanodrugs

  Participated · Series A · Jul 2015

  LEON Nanodrugs (branded as LEON) builds NANO systems, a hardware platform that uses the company’s proprietary FR-JET mixing technology to manufacture nanoparticles at GMP scale. The equipment is aimed at overcoming the production bottlenecks that currently hinder RNA medicines, cancer vaccines, cell and gene therapies, and other personalized treatments. LEON’s technology supports small-batch, rapid-turnaround workflows and allows customers to move from early development to commercial volumes without a full process redesign, reducing operational risk and time-to-market. Investor interest is growing as demand for scalable nanoparticle production rises; the company says customer demand is already “growing” and its systems are “market-ready.” Proceeds from the latest round will fund the global market launch of the NANO platform and expansion of the company’s commercial footprint. Financial details such as revenue or unit shipments were not disclosed, but management emphasized that the fundraising was significantly oversubscribed, indicating strong investor confidence. LEON positions itself at an inflection point, expecting to become a leading provider in the rapidly expanding field of nanoparticle-based therapeutics.

• Curetis

  Participated · Series B · Nov 2014

  Curetis develops and commercializes the Unyvero molecular diagnostic platform that delivers rapid multi-parameter pathogen and antibiotic-resistance marker detection in only a few hours. The company intends to further develop and validate complementary technology assets and associated IP, fund clinical trials, and integrate the recently acquired GEAR database and assets into its platform. The financing is targeted to accelerate R&D activities and to broaden the pipeline of applications for Unyvero. Founded in 2007 and based in Holzgerlingen near Stuttgart, Germany, Curetis focuses on fast, cost-effective diagnostics for severe infectious diseases. To date the company has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Brussels and over EUR 63.5 million in private equity, and it has now entered into an EIB debt facility up to EUR 25 million. The funding is expected to cover up to 50% of Curetis’s expected medium-term R&D project requirements, including R&D staff costs, external R&D operating expenses and related capital expenditures. Curetis is a German developer of next-generation molecular diagnostics centered on its Unyvero platform. The Unyvero system is a comprehensive diagnostics platform for severe infectious diseases in hospitalized patients, using a variety of cartridges to diagnose conditions such as pneumonia and implant and tissue infections within four to five hours. The Unyvero P50 Pneumonia and i60 Implant and Tissue Infection applications are already approved for use in Europe. Curetis will use the new funds to support the European product rollout and to run a U.S. clinical trial of Unyvero; the company is also looking to bring its tests to Asian markets. Management said it is pursuing attractive future exit opportunities including strategic partnerships, M&A or an IPO. The new financing increases the company’s total equity raised to more than $79.2 million and, according to the company, finances operations well into 2017. Curetis AG announced the closing of a Series B financing totaling EUR 12.5 million. The round was led by HBM Partners, which took an EUR 6.0 million equity stake in Curetis. Dr. Alexander Asam of HBM Partners will join Curetis' supervisory board. The announcement was presented as portfolio news. No other investors or financing instruments were disclosed in the article. No operating metrics, past rounds, founding year, or location were provided. Curetis, founded in 2007 and based in Holzgerlingen near Stuttgart, Germany, develops and commercializes rapid molecular diagnostic solutions. Its core product, the Unyvero System, is designed to detect pathogens and antibiotic resistance markers within a few hours. The technology aims to enable clinicians to diagnose causes of severe infections faster and begin targeted antibiotic regimens immediately for critically ill patients. The company is led by CEO Oliver Schacht, PhD, with CTO Andreas Boos and COO Johannes Bacher. Curetis has been advancing commercialization alongside continued development of its diagnostic platform. Recent financing activity has supported its near-term growth and Board expansion. Curetis AG develops and commercializes in vitro diagnostic products for infectious diseases, centered on its Unyvero product platform. The company intends to use newly raised funds to prepare for commercial launch and roll-out of Unyvero together with a CE‑marked IVD test cartridge for pneumonia and antibiotic resistances. Unyvero is a hardware platform designed to detect a broad panel of bacteria and antibiotic resistances from a single sample in one run. Curetis is based in Holzgerlingen, Germany, and recently appointed Oliver Schacht, PhD, as CEO. Financially, the company has been capitalizing its commercialization push through equity financing, including a prior €18.5m raise in 2009.

No current team members are available.